Citations (15)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Luigi Celio & Chiara Fabbroni. (2018) Pro-netupitant/palonosetron (IV) for the treatment of radio-and-chemotherapy-induced nausea and vomiting. Expert Opinion on Pharmacotherapy 19:11, pages 1267-1277.
Read now
Read now
Vito Lorusso. (2016) Management of chemotherapy-induced nausea and vomiting by risk profile: role of netupitant/palonosetron. Therapeutics and Clinical Risk Management 12, pages 917-925.
Read now
Read now
Giovana Paula Rezende Simino, Lays Pires Marra, Eli Iola Gurgel de Andrade, Francisco de Assis Acúrcio, Ilka Afonso Reis, Vânia Eloisa De Araújo & Mariângela Leal Cherchiglia. (2016) Efficacy, safety and effectiveness of ondansetron compared to other serotonin-3 receptor antagonists (5-HT3RAs) used to control chemotherapy-induced nausea and vomiting: systematic review and meta-analysis. Expert Review of Clinical Pharmacology 9:9, pages 1183-1194.
Read now
Read now
Articles from other publishers (12)
Metin Deniz KARAKOÇ. (2022) Kanser Hastalarında Polifarmasi ve İlaç EtkileşimleriPolypharmacy and Drug Interactions in Cancer Patients. Adnan Menderes Üniversitesi Sağlık Bilimleri Fakültesi Dergisi 6:1, pages 31-42.
Crossref
Crossref
GVM Chamath Fernando & Jayamangala Sampath Kondasinghe. (2021) Mechanistic approach to the management of cancer-related nausea and vomiting in a palliative care resource-limited setting. International Journal of Palliative Nursing 27:7, pages 362-366.
Crossref
Crossref
Roberta Caputo, Marina Elena Cazzaniga, Andrea Sbrana, Rosalba Torrisi, Ida Paris, Monica Giordano, Vincenzo Montesarchio, Valentina Guarneri, Laura Amaducci, Domenico Bilancia, Giuseppina Cilenti, Alessandra Fabi, Elena Collovà, Alessio Schirone, Erminio Bonizzoni, Luigi Celio, Sabino De Placido & Michelino De Laurentiis. (2020) Netupitant/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multi-cycle, phase II study. BMC Cancer 20:1.
Crossref
Crossref
Tatsuhiko Sakamoto, Yoshitaka Saito, Masaki Kobayashi, Takehiro Yamada, Yoh Takekuma, Masato Nakai, Koji Ogawa, Ken Iseki & Mitsuru Sugawara. (2019) Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. Supportive Care in Cancer 28:7, pages 3251-3257.
Crossref
Crossref
Yuki Okada, Koji Oba, Naoto Furukawa, Yoshimasa Kosaka, Kenji Okita, Satoshi Yuki, Yoshito Komatsu, Luigi Celio & Matti Aapro. (2019) One-Day Versus Three-Day Dexamethasone in Combination with Palonosetron for the Prevention of Chemotherapy-Induced Nausea and Vomiting: A Systematic Review and Individual Patient Data-Based Meta-Analysis. The Oncologist 24:12, pages 1593-1600.
Crossref
Crossref
Luigi Celio, Erminio Bonizzoni, Emma Zattarin, Paolo Codega, Filippo de Braud & Matti Aapro. (2019) Impact of dexamethasone-sparing regimens on delayed nausea caused by moderately or highly emetogenic chemotherapy: a meta-analysis of randomised evidence. BMC Cancer 19:1.
Crossref
Crossref
Xiaodong Wang, Zhi-Yi Zhang, Jing Wang & Vikram Kansra. (2019) A Phase 1 Assessment of the QT Interval in Healthy Adults Following Exposure to Rolapitant, a Cancer Supportive Care Antiemetic. Clinical Pharmacology in Drug Development 8:5, pages 603-611.
Crossref
Crossref
Nicolas Jovenin, Audrey Eche-Gass, Stéphane Chèze, Vincent Launay-Vacher, Didier Mayeur, Jean-Baptiste Rey, Florence Joly, Ivan Krakowski & Florian Scotté. (2019) Nausées-vomissements induits par les traitements anti-cancéreux (NVITAC) : quelle prise en charge en 2018 ? Mise à jour du référentiel AFSOS. Bulletin du Cancer 106:5, pages 497-509.
Crossref
Crossref
Jung-Hee Ryu, Young-Tae Jeon, Byunghun Min, Jin-Young Hwang & Hye-Min Sohn. (2018) Effects of palonosetron for prophylaxis of postoperative nausea and vomiting in high-risk patients undergoing total knee arthroplasty: A prospective, randomized, double-blind, placebo-controlled study. PLOS ONE 13:5, pages e0196388.
Crossref
Crossref
Gábor Kovács, Antonio Wachtel, Elena Basharova, Tulla Spinelli, Pierre Nicolas & Edita Kabickova. (2017) Palonosetron compared with ondansetron in pediatric cancer patients: multicycle analysis of a randomized Phase III study. Future Oncology 13:19, pages 1685-1698.
Crossref
Crossref
Umberto Restelli, Gabriella Saibene, Patrizia Nardulli, Roberta Di Turi, Erminio Bonizzoni, Francesca Scolari, Tania Perrone, Davide Croce & Luigi Celio. (2017) Cost-utility and budget impact analyses of the use of NEPA for chemotherapy-induced nausea and vomiting prophylaxis in Italy. BMJ Open 7:7, pages e015645.
Crossref
Crossref
Chao Liu, Mei Hui, Peng Quan & Liang Fang. (2016) Drug in adhesive patch of palonosetron: Effect of pressure sensitive adhesive on drug skin permeation and in vitro-in vivo correlation. International Journal of Pharmaceutics 511:2, pages 1088-1097.
Crossref
Crossref